A Tale of the Tape - Equity Investor Activity in Medtech - Q2, 2026

Medtech venture funding bounced back in the second quarter of 2026, and one company did a lot of the heavy lifting. According to PitchBook's newly published Q2 2026 Medtech Report, VC deal value climbed to $4.9 billion, up from $3.7 billion in Q1 and comfortably above the $4.1 billion quarterly average the sector has posted since 2024. The catalyst: MiRus, a spine and orthopedic implant maker built around a proprietary molybdenum-rhenium alloy it calls MoRe, closed a $1.5 billion late-stage round backed by Boston Scientific at a $4.4 billion post-money valuation. That single deal accounts for nearly a third of the quarter's total VC dollars.

But the headline number masks a more mixed picture underneath. Deal counts kept falling — down 11.9% quarter-over-quarter after an 12.5% drop in Q1 — meaning fewer companies are raising, even as the biggest rounds get bigger. Five deals crossed $100 million in Q2, including Aidoc's $150 million Series E for its radiology AI platform, and $100 million rounds each for CeQur Simplicity, Pulnovo Medical, and GT Medical Technologies.

Surgical devices and tools remains the sector's center of gravity, pulling in $3 billion in Q2 and $8.2 billion on a trailing-twelve-month basis across 78 deals. Diagnostics and life sciences, by contrast, is still stuck near the bottom: investment fell to $388.7 million, nearly 59% below its post-COVID rebound average and down 42.8% year-over-year, as early-stage biotech funding stays weak.

One trend worth watching: brain-computer interface and regenerative medicine companies had a notable quarter. Re-Emerge DBS raised $30 million for an implantable deep-brain-stimulation system targeting cognitive impairment after traumatic brain injury. Sonomind closed roughly $23.5 million for a focused-ultrasound depression treatment. And Shenfu Jianxing, a Fudan University spinout, raised about $44.1 million for a brain-spine interface that helped patients regain leg movement within 24 hours of surgery. PitchBook expects BCI and regenerative solutions to keep taking a bigger share of medtech dollars going forward.

Exit activity stayed strong across the board. VC exits hit $4.3 billion for the fourth straight quarter above $4 billion, led by Alamar Biosciences' $219.9 million IPO. PE told a different story: deal count dropped 24.1% quarter-over-quarter to 41, and deal value fell 14.1%, continuing a two-quarter slowdown from 2025's much hotter pace. The largest PE transaction was Avanos Medical's $1.3 billion take-private.

The takeaway for anyone watching medtech capital markets: don't read the Q2 rebound as broad-based recovery. Current investments are concentrated — one mega-round, one segment, and a shrinking pool of companies actually getting funded. Median deal size and pre-money valuations are still climbing (up to $11.6 million and $35.0 million year-to-date, respectively), which suggests investors are writing fewer, larger checks rather than spreading capital wider. Worth watching whether that concentration continues into Q3, or whether the smaller end of the market starts to catch up.

My takeaway is quality counts. Having all your ducks in a row, positioning your startup strategically within the healthcare delivery and reimburesement landscape and/or having your heathcare economics tied down through your clinicals is more important than ever.

For more information on how Performance Transformation can help you navigate the funding and commercializaiton path, please contact us at terry@performtransform.com.

© 2026, Performance Transformation, Inc.